Jazz Pharmaceuticals (JAZZ) to Release Quarterly Earnings on Tuesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) will likely be releasing its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Jazz Pharmaceuticals to post earnings of $6.49 per share and revenue of $1.1660 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

Jazz Pharmaceuticals Trading Up 1.5%

Shares of NASDAQ JAZZ opened at $172.19 on Monday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. The business’s 50 day moving average price is $167.92 and its 200-day moving average price is $149.40. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The company has a market cap of $10.46 billion, a price-to-earnings ratio of -28.37, a PEG ratio of 0.93 and a beta of 0.26.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 77,500 shares of the stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the transaction, the director directly owned 393,332 shares in the company, valued at approximately $69,938,362.92. This trade represents a 16.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the transaction, the senior vice president directly owned 19,508 shares of the company’s stock, valued at $3,306,801.08. This trade represents a 10.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 84,398 shares of company stock valued at $14,957,430. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in JAZZ. Ieq Capital LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $534,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 53.1% during the second quarter. EverSource Wealth Advisors LLC now owns 902 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 313 shares during the last quarter. UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 81 shares in the last quarter. Graham Capital Management L.P. purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $206,000. Finally, Quantessence Capital LLC purchased a new position in Jazz Pharmaceuticals in the third quarter worth $212,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on JAZZ. Morgan Stanley reaffirmed an “overweight” rating and issued a $225.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Needham & Company LLC upped their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Royal Bank Of Canada set a $194.00 price objective on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a report on Monday, November 17th. JPMorgan Chase & Co. dropped their target price on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Fourteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.67.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.